Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome

What Was Tested

This randomized controlled trial paper looks at BNP (Nesiritide) in the context of anemia.

The present study examines in patients with advanced CHF, chronic renal insufficiency, and anemia the effects of beta-EPO on left ventricular (LV) systolic diameter and volume (LVSD and LVSV), LV diastolic diameter and volume (LVDD and LVDV), LV mass, LV ejection fraction (LVEF), pulmonary artery pressure (PAP), and B-type natriuretic peptide (BNP) levels.

Why It Was Studied

Although anemia is frequently found in congestive heart failure (CHF), little is known about the effect of its correction with erythropoietin (EPO) on cardiac structure and function.

Who Took Part

The abstract describes 26 patients taking part.

The age groups tagged for this paper are older adults, both men and women.

The researchers performed a randomized double-blind controlled study of correction of anemia with subcutaneous EPO for 4 months (group A, 26 patients) using saline as the placebo in the control group (group B, 25 patients).

The researchers then maintained the EPO treatment in the treated group for another 8 months.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.

As a double-blind BNP (Nesiritide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with BNP (Nesiritide) could be set against what happens without it.

A time span of 4 months appears in the methods.

Both groups received oral iron throughout the total 12-month period.

Echocardiographic evaluation, BNP levels, and hematological parameters are reported at 4 and 12 months.

What Was Measured

The subject headings attached to it are Anemia, Creatinine, Erythropoietin, Heart Failure, Kidney Failure, Chronic, Myocardial Contraction and Natriuretic Peptide, Brain.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of BNP (Nesiritide) in 26 patients in people with anemia over 4 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2007 (American heart journal), a journal based in United States.

More context: the BNP (Nesiritide) compound page, Anemia research.